source
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.Fierce Biotech · 11d ago↗ source
- Half-century after IL-2 discovery, its impact on HIV, cancer and blood safety is highlightedRobert Gallo marks the 50-year anniversary of the 1976 paper that described interleukin-2, one of the first cytokines identified and essential for T-cell growth. He notes that IL-2 enabled the dis…
- Hengrui secures $15.2 billion Bristol Myers deal and pivots to co-development with Western partners